테라에프에이

비상장계속사업자

TERAFA Co. Ltd

홍성관

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

테라에프에이

Business Reg. No. 3058162797 · CEO 홍성관

I.Investment Overview

Target테라에프에이 (3058162797)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명테라에프에이
영문명TERAFA Co. Ltd
대표자홍성관
사업자등록번호3058162797
법인등록번호1601110157267
설립일2003.05.01

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW217.52021338.12022364.12023179.62024257.22025
영업이익100M KRW5.9202119.2202214.320238.920245.62025
순이익100M KRW4.220218.120225.320231.920241.72025
Item20252024202320222021
자산총계260.6억원235.6억원274.8억원281.1억원140.3억원
부채총계180.6억원157.2억원198.3억원209.9억원77.2억원
자본총계80억원78.3억원76.5억원71.2억원63.1억원
매출액257.2억원179.6억원364.1억원338.1억원217.5억원
영업이익5.6억원8.9억원14.3억원19.2억원5.9억원
순이익1.7억원1.9억원5.3억원8.1억원4.2억원

VI.Financial Ratios

FY2025 basis

2.19%

영업이익률

0.67%

순이익률

0.66%

ROA

2.14%

ROE

225.67%

부채비율

30.71%

자기자본비율

VII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

테라에프에이 투심보고서 | Alpha Lenz